| Future Health Pharma GmbH - Nuvaxovid 0.5 ml, Injektionsdispersion | | 68473 | | 01 | | Nuvaxovid 0.5 ml | | Injektionsdispersion | | J07BX03 | | Covid-19 Vaccines | | 12.04.2022 | | |
| | Composition | | SARS CoV-2 rS NVX-CoV2373 5 µg, adjuvans Matrix-M: saponinum Fraction-A 42.5 µg et saponinum Fraction-C 7.5 µg ex Quillaja saponariae Molina extractum purificatum, cholesterolum, phosphatidylcholinum, int-rac-alpha-tocopherolum, kalii dihydrogenophosphas, kalii chloridum, dinatrii phosphas dihydricus, dinatrii phosphas heptahydricus, natrii dihydrogenophosphas monohydricus, natrii chloridum, polysorbatum 80, natrii hydroxidum q.s. ad pH, acidum hydrochloridum q.s. ad pH, aqua ad iniectabile q.s. ad praeparationem pro 0.5 ml corresp., natrium 4.0 mg, kalium 0.003 mg. | | Packungsbestandteile | | Injektionsdispersion | | | | | | Principe actif | Concentr. |
|---|
| Sars Cov-2 rs Nvx-Cov2373 | 5 µg |
| | | | Agents auxilliaires | Concentr. | informations additionels |
|---|
| Cholesterol | | | | Disodium Phosphate Dihydrate | | | | Disodium Phosphate Heptahydrate | | | | Ex Quillaja Saponariae Molina Extractum Purificatum | | | | Int-Rac-Alpha-Tocopherolum | | | | Potassium Chlorure | | | | Potassium Dihydrogenophosphate | | | | Sodium Chlorure | | | | Sodium Dihydrogenophosphate Monohydrate | | | | Sodium Hydroxide | | | | Phosphatidylcholine | | | | Polysorbatum 80 | | | | Saponinum Fraction-A | 42.5 µg | adjuvans Matrix-M | | Saponinum Fraction-C | 7.5 µg | |
|
| | numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| Aucune entrée n'a été trouvée. |
|
|
